EYPT, US30233G2093

JonesTrading downgrades EyePoint Pharmaceuticals stock to Hold

Published on 10/24/2026 at 20:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 brought a USD 94.5 million GAAP loss in the quarter ended June 30, 2026. EyePoint Pharmaceuticals stock faces a USD 1.00 target, down from USD 5.00.

Analyst ratings and quarterly loss

JonesTrading downgraded EyePoint Pharmaceuticals to Hold on October 23, 2026.
EyePoint reported a GAAP net loss of USD 94.5 million for the quarter ended June 30, 2026.
Yahoo Finance lists November 4, 2026 as the next earnings date.

EYPT, US30233G2093, Illustration mit AI erstellt.

EyePoint Pharmaceuticals (US30233G2093) was downgraded to Hold by JonesTrading on October 23, 2026, according to Markets Insider. The latest analyst action followed a sharp deterioration in expectations for the clinical-stage biotechnology company.

On October 20, 2026, RBC Capital cut its price target for EyePoint from USD 5.00 to USD 1.00 while retaining a Sector Perform rating, as Markets Insider reported. The target change puts the latest analyst view close to the company's Nasdaq quotation rather than the much higher targets still listed in some consensus tables.

Second-quarter loss reached USD 94.5 million

EyePoint reported a GAAP net loss of USD 94.47 million for the quarter ended June 30, 2026, compared with a USD 59.43 million loss in the year-earlier quarter, according to Markets Insider. Quarterly revenue was USD 507,000, down from USD 5.33 million a year earlier. The figures underline why analyst attention has shifted from near-term sales to clinical execution and funding capacity.

Nasdaq range remains wide

EyePoint last traded at USD 0.40 on Nasdaq on October 23, 2026 at 4:00 p.m. ET. Its 52-week range was USD 0.39 to USD 19.11, leaving the stock close to its low and far below its high. Market capitalization stood at USD 33.9 million on the same date.

Cash and reporting date matter next

Cash and cash equivalents were USD 110.46 million at June 30, 2026, while operating cash flow was negative USD 62.35 million in the second quarter. Yahoo Finance lists November 4, 2026 as the next earnings date. That date gives investors the next scheduled point for updates on liquidity, development spending and the remaining clinical program.

German euro quotation

The last available euro price came from Tradegate at EUR 0.39 on October 23, 2026 at 12:02 p.m. CEST. On Nasdaq, the stock last traded at USD 0.40 on October 23, 2026 at 4:00 p.m. ET, keeping the two venue quotations clearly separated.